Advancing gene therapy
for neurodegenerative ophthalmic diseases

GenSight Biologics CEO Laurence Rodriguez spoke with Le Journal des Biotechs on Boursorama to discuss the Company's recent progress and key priorities.

Watch the interview

GenSight congratulates co-founders Dr. José-Alain Sahel and Dr. Botond Roska on receiving the António Champalimaud Vision Award, the world's largest prize in vision, recognizing decades of research into the mechanisms of sight and new therapies to restore it, notably optogenetics.

Our CEO, Laurence Rodriguez, joins the LEEM Board of Directors and Executive Committee.

Learn more

CONGRATULATIONS!
GenSight Biologics co-founder José-Alain Sahel was awarded the prestigious 2026 ARVO Proctor Medal for his leadership and groundbreaking achievements in the field of ophthalmic research.

GenSight's 2025 URD is now available.

Go to URD

Clinical trials

GS010; (lenadogene nolparvovec) is completing its clinical development while GS030 is currently running PIONEER Phase I/II

Check status

Our technologies

Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics

View our Technologies

GENSIGHT BIOLOGICS S.A.
74, rue du Faubourg Saint-Antoine
75012 Paris
FRANCE

Terms of use
Sitemap
Contact
Credits
Cookies management

Go back to the page of the page